Targeting FGFR3 in multiple myeloma: Inhibition of t(4;14)-positive cells by SU5402 and PD173074

Leukemia

Volumn 18, Issue 5, 2004, Pages 962-966

  Grand, E K ^a,b   Chase, A J ^a,c   Heath, C ^b   Rahemtulla, A ^b   Cross, N C P ^a,c  

^a WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

FGFR3; Myeloma; PD173074; SU5402; t(4; 14)

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [2,4 DIMETHYL 5 (2 OXO 1,2 DIHYDROINDOL 3 YLIDENEMETHYL) 1H PYRROL 3 YL]PROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 3 [[3 (2 CARBOXYETHYL) 4 METHYLPYRROL 2 YL]METHYLENE] 2 INDOLINONE; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMATINIB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PD 173074; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL VIABILITY; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; CHROMOSOME 14; CHROMOSOME 4; DRUG ANTAGONISM; GENE TRANSLOCATION; GENETICS; HUMAN; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; HUMANS; MULTIPLE MYELOMA; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; TRANSLOCATION, GENETIC;

EID: 2342566403     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403347     Document Type: Article

References (21)

1. Chesi M, Nardin, E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-264.
2. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 199; 5: 1063-1071.
3. Onose H, Emoto N, Sugihara H, Shimizu K, Wakabayashi I. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol 1999; 140: 169-173.
4. Yoshimura N, Sano H, Hashiramoto A, Yamada R, Nakajima H, Kondo M et al. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR1) in human breast cancer. Clin Immunol Immunopathol 1998; 89: 28-34.
5. Wagner M, Lopez ME, Cahn M, Korc M. Suppression of fibroblast growth factor receptor signalling inhibits pancreatic cancer growth in vitro and in vivo. Gastroenterology 1998; 114: 798-807.
6. Macdonald DHC, Reiter A, Cross NCP. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FCFR1. Acta Haematol 2002; 107: 101-107.
7. Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 2001; 61: 8371-8374.
8. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20.
9. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729-736.
10. Soverini S, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica 2002; 87: 1036-1040.
11. Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol 2002; 118: 514-520.
12. Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000; 95: 992-998.
13. Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001; 97: 2413-2419.
14. Smedley D, Demiroglu A, Abdul-Rauf M, Heath C, Cooper C, Shipley J et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia 1999; 1: 349-355.
15. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-4160.
16. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997; 276: 955-960.
17. Skaper SD, Kee WJ, Facci L, Macdonald G, Doherty P, Walsh FS. The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects. J Neurochem 2000; 75: 1520-1527.
18. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL et al. The t(8;22) in chronic myeloid leukaemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98: 3778-3783.
19. Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553-3562.
20. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy Jr J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003; 101: 2374-2376.
21. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. in multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529.